ImmunityBio, Inc.'s advances with Anktiva & rBCG show promise amid financial hurdles. Click here to find out why IBRX stock ...

Teacher Retirement System of Texas grew its stake in shares of ImmunityBio, Inc. (NASDAQ:IBRX – Free Report) by 20.4% in the ...

We recently published a list of 10 Stocks Outperform Broader Market Last Week. In this article, we are going to take a look ...

D. Boral Capital reaffirmed their buy rating on shares of ImmunityBio (NASDAQ:IBRX – Free Report) in a report issued on Monday,Benzinga reports. They currently have a $30.00 target price on the stock.

ImmunityBio, Inc.’s IBRX share price has surged by 20.86%, which has investors questioning if this is right time to sell.

CULVER CITY, Calif., March 26, 2025--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, invites current and prospective investors to its Investor Day program to be held on Tuesday ...

We recently compiled a list of the 12 Stocks Under $10 With High Upside Potential. In this article, we are going to take a look at where ImmunityBio, Inc. (NASDAQ:IBRX) stands against the other stocks ...

Despite Anktiva's potential, IBRX remains a "sell" due to operational, competitive, and financial challenges outweighing its prospects. ImmunityBio markets Anktiva, a "novel IL-15 receptor ...

ImmunityBio ( NASDAQ:IBRX ) Full Year 2024 Results Key Financial Results Revenue: US$14.7m (up by US$14.1m from FY... The market remained flat over the last week but is up 23% over the past year ...